Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma, Ewing × Dactinomycin × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 7 Rhabdomyosarcoma 7 Malignant mesenchymal tumor 4 Wilms Tumor 3 Rhabdomyosarcoma, Embryonal 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Kidney Neoplasms 2 Gestational Trophoblastic Disease 2 Sarcoma, Ewing 1 Rhabdomyosarcoma, Alveolar 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pleuropulmonary blastoma 1 Lymphoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hydatidiform Mole 1 Choroid Plexus Neoplasms 1 Brain Neoplasms 1 Blast Crisis 1 Beckwith-Wiedemann Syndrome 1

Interventions

Vincristine 2 Ifosfamide 2 Etoposide 2 Doxorubicin 2 Cyclophosphamide 2 Busulfan 2 treosulfan 1 ganitumab 1 etoposide phosphate 1 Zoledronic Acid 1 Triptorelin Pamoate 1 Temozolomide 1 Radiosurgery 1 Radiation 1 Melphalan 1 Irinotecan 1 FANG vaccine 1 Diphosphonates 1 Dactinomycin 1 Cyproheptadine 1 Congresses as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02063022 2022-09-19

EW-1

Italian Sarcoma Group

Phase 3 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡